SCHEMBL10179540

SCHEMBL10179540

CC(C)(C)c1cccc(S(=O)(=O)CC(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.50
CYP2C19 P33261 3/20 0.50
CYP2C9 P11712 2/20 0.49
CYP2D6 P10635 1/20 0.49
ACHE P22303 3/20 0.49
ALDH1A1 P00352 3/20 0.43
HPGD P15428 2/20 0.43
HDAC8 Q9BY41 2/20 0.42
HDAC3 O15379 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
POLB P06746 2/20 0.40
NPSR1 Q6W5P4 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10181255 0.86 CYP3A4 (0.47) CYP3A4CYP2C19CYP2C9CYP2D6ACHE
SCHEMBL9303097 0.84 PNMT (0.44) CYP3A4CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL10179763 0.82 PSIP1 (0.52) CYP3A4CYP2C19CYP2C9CYP2D6ACHE
SCHEMBL10179515 0.79 ALDH1A1 (0.52) ACHEALDH1A1HPGDCA1CA2
SCHEMBL10145039 0.77 ACHE (0.50) CYP3A4CYP2C19ACHEALDH1A1HDAC8
SCHEMBL776129 0.77 MEN1 (0.42) CYP3A4CYP2C19CYP2C9CYP2D6CA1
SCHEMBL26569860 0.77 ACHE (0.49) ACHEALDH1A1HPGDHDAC8HDAC3
SCHEMBL10180377 0.77 LOXL2 (0.41) CYP3A4CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL10179564 0.77 KAT6A (0.40) CYP3A4CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL13483410 0.77 HDAC8 (0.45) CYP3A4CYP2C19CYP2C9CYP2D6ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210024498-A1 TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF MEDICONNS SHANGHAI BIOPHARMACEUTICAL CO LTD (CN) 2021-01-28 US disclosed
US-20130244122-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME ONUKI MASAMICHI (JP) 2013-09-19 US disclosed
US-20120219866-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2012-08-30 US disclosed
EP-2475041-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME Mitsubishi Chemical Corporation (JP) 2012-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024498-A1 TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF PRLHR, DRD2, AVPR2 CYP3A4 542/4885CYP2C19 719/4885CYP2C9 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.